This industry research report segments the global hemophilia B market by disease severity (mild, moderate, and severe), by disease management (on-demand therapy, prophylaxis, and inhibitors), and by geography (APAC, EMEA, and the Americas). This report also includes a section on the key trends, drivers, and leading vendors in this market, including Baxter, Grifols, Novo Nordisk, and Pfizer.
Technavio’s market research analysts estimate the global hemophilia B market to grow at a CAGR of around 4% between 2015 and 2019. The advent of plasma-derived and recombinant factor replacement therapeutics is expected to boost this market’s growth in the next four years. The Americas dominate the global market for hemophilia B, occupying around 44% of the total market share. Much of this region’s growth can be attributed to the increase in prophylactic treatment and development of long-acting hemophilia B therapeutic products.
The new market research report from Technavio provides a breakdown and analysis of the hemophilia B segments by technology.
“Of late, several pharmaceutical companies are developing gene therapy candidates, as the available drugs are quite expensive. These gene therapy products offer a permanent cure for hemophilia B by direct delivery of the gene producing human Factor IX into the patients’ liver cells. For instance, SPK-FIX by Spark Therapeutics and Pfizer is soon to be launched in the market,” says Imran Mushtaq, Lead Analyst, Healthcare, Technavio Research.
Prophylactic treatment is fast gaining popularity among physicians and patients. This treatment lowers the bleeding chances and maintains optimum levels of clotting factors. It is more cost-effective than the on-demand therapy. Various long-acting hemophilia B prophylactic drugs such as rFIX-FP by CSL Behring are under different developmental stages. Moreover, physicians prefer prophylactic therapy because of its superior pharmacokinetic profile. In 2014, about 16% individuals with hemophilia B worldwide used prophylactic therapy. However, low awareness levels of the disease are limiting the use of this treatment.
The key vendors in the global hemophilia B market are Baxter, Grifols, Novo Nordisk, and Pfizer. Competitiveness in this market is expected to deepen with an increase in strategic alliances and technological advancements.
A more detailed analysis is available in the Technavio report, Global Hemophilia B Market 2015-2019 – Industry Analysis.
We can customize reports by other regions and specific segments upon request.
Other Related Reports:
